Monday 1 April 2019

Panvigilance—a strategy to integrate biomarkers in clinical trials to enhance drug safety

Modern medicines have positively contributed to public health and changed the ways human diseases are prevented and treated. Yet, most drugs are not without side effects. Adverse drug reactions (ADRs) rank among the leading causes of morbidity and mortality worldwide. The current paradigm of drug development can detect only the most common ADRs in clinical trials.

* This article was originally published here